Mikel Berdud

Personal Details

First Name:	Mikel
Middle Name:
Last Name:	Berdud
Suffix:
RePEc Short-ID:	pbe1130
	https://www.ohe.org/about-us/meet-team/mikel-berdud

Affiliation

Office of Health Economics

London, United Kingdom
http://www.ohe.org/
RePEc:edi:ohecouk (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

1. Mikel Berdud & Kalipso Chalkidou & Emma Dean & Jimena Ferraro & Lou Garrison & Cassandra Nemzoff & Adrian Towse, 2019. "The Future of Global Health Procurement: Issues around Pricing Transparency," Working Papers 507, Center for Global Development.

   Cited by:

   1. Brendan Shaw & Jorge Mestre-Ferrandiz, 2020. "Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices," PharmacoEconomics, Springer, vol. 38(2), pages 125-134, February.
   2. Riccaboni, Massimo & Swoboda, Torben & Van Dyck, Walter, 2022. "Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model," Health Policy, Elsevier, vol. 126(6), pages 534-540.

2. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "Motivational Capital and Incentives in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1403, Departamento de Economía - Universidad Pública de Navarra.
   • Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2012. "Motivational Capital and Incentives in Health Care Organisations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1209, Departamento de Economía - Universidad Pública de Navarra.
   • Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "Motivational Capital and Incentives in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1402, Departamento de Economía - Universidad Pública de Navarra.

   Cited by:

   1. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "A Pilot Inquiry on Incentives and Intrinsic Motivation in Health Care: the Motivational Capital Explained by Doctors," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1401, Departamento de Economía - Universidad Pública de Navarra.

3. Mikel Berdud & Juan M. Cabasés Hita, 2012. "Incentives Beyond the Money and Motivational Capital in Health Care Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1201, Departamento de Economía - Universidad Pública de Navarra.

   Cited by:

   1. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "A Pilot Inquiry on Incentives and Intrinsic Motivation in Health Care: the Motivational Capital Explained by Doctors," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1401, Departamento de Economía - Universidad Pública de Navarra.

4. Mikel Berdud & Juan M. Cabasés & Jorge Nieto, 2012. "Incentives Beyond the Money: Identity and Motivational Capital in Public Organizations," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1214, Departamento de Economía - Universidad Pública de Navarra.

   Cited by:

   1. Mikel Berdud & Juan M. Cabasés Hita & Jorge Nieto, 2014. "A Pilot Inquiry on Incentives and Intrinsic Motivation in Health Care: the Motivational Capital Explained by Doctors," Documentos de Trabajo - Lan Gaiak Departamento de Economía - Universidad Pública de Navarra 1401, Departamento de Economía - Universidad Pública de Navarra.

Articles

1. Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.

   Cited by:

   1. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
   2. Don Husereau & Brian Feagan & Carl Selya-Hammer, 2018. "Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching," Applied Health Economics and Health Policy, Springer, vol. 16(3), pages 279-288, June.
   3. Katharina E. Blankart & Friederike Arndt, 2020. "Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany," IJERPH, MDPI, vol. 17(11), pages 1-14, June.
   4. Jaime Espin & Michael Schlander & Brian Godman & Pippa Anderson & Jorge Mestre-Ferrandiz & Isabelle Borget & Adam Hutchings & Steven Flostrand & Adam Parnaby & Claudio Jommi, 2018. "Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 803-817, December.
   5. Steven Simoens & Ira Jacobs & Robert Popovian & Leah Isakov & Lesley G. Shane, 2017. "Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis," PharmacoEconomics, Springer, vol. 35(10), pages 1047-1062, October.
   6. François Bocquet & Anaïs Loubière & Isabelle Fusier & Anne-Laure Cordonnier & Pascal Paubel, 2016. "Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience," PharmacoEconomics, Springer, vol. 34(11), pages 1173-1186, November.
   7. Ghyli Kirshner & Peter Makai & Chiara Brouns & Lonneke Timmers & Ron Kemp, 2024. "The impact of an ‘evergreening’ strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuz," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(7), pages 1147-1163, September.
   8. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
   9. Hye-Jae Lee & Euna Han & Hyero Kim, 2020. "Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 557-566, August.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 11 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.

1. NEP-HEA: Health Economics (6) 2012-03-08 2014-04-11 2014-04-11 2018-05-21 2018-10-15 2020-08-31. Author is listed
2. NEP-CTA: Contract Theory and Applications (5) 2012-03-08 2013-01-07 2014-04-11 2014-04-11 2021-05-31. Author is listed
3. NEP-HRM: Human Capital and Human Resource Management (4) 2012-03-08 2013-01-07 2014-04-11 2014-04-11
4. NEP-COM: Industrial Competition (2) 2018-10-15 2020-08-31
5. NEP-EUR: Microeconomic European Issues (2) 2018-05-21 2018-05-21
6. NEP-GER: German Papers (2) 2014-04-11 2014-04-11
7. NEP-ENV: Environmental Economics (1) 2018-05-21
8. NEP-INO: Innovation (1) 2018-10-15
9. NEP-INT: International Trade (1) 2018-05-21
10. NEP-MIC: Microeconomics (1) 2013-01-07
11. NEP-ORE: Operations Research (1) 2020-08-31
12. NEP-REG: Regulation (1) 2019-05-06
13. NEP-TID: Technology and Industrial Dynamics (1) 2018-10-15

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Mikel Berdud should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.